Lanreotide Autogel 120 mg SC q4w (well-differentiated GEP-NET G1/G2; CLARINET)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-LANREOTIDE`

ID	`REG-LANREOTIDE-AUTOGEL-GI-NET`
Type	Regimen
Status	reviewed 2026-05-03 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-CLARINET-CAPLIN-2014` `SRC-NCCN-NET-2025`

Notes

CLARINET (Caplin NEJM 2014): lanreotide 120 mg q4w vs placebo in well-differentiated G1/G2 non-functioning GEP-NET (n=204). mPFS not reached vs 18.0 mo (HR 0.47, p<0.001). Also shown in PROMID (Rinke JCO 2009) with octreotide LAR 30 mg q4w for midgut NET: mPFS 14.3 vs 6.0 mo (HR 0.34). Both trials establish SSA as antiproliferative standard (not just symptom control). CLARINET OLE (96-week extension) confirmed durable benefit in stable/non-progressive disease. Octreotide LAR 30 mg q4w is a valid alternative to lanreotide (no head-to-head; both NCCN Category 1 for GI-NET). Lanreotide used here as it has the broader CLARINET GEP-NET data set. STUB pending §6.1 signoff.

Used By

Indication

IND-GI-NET-ADVANCED-1L-LANREOTIDE - IND-GI-NET-ADVANCED-1L-LANREOTIDE

Regimen

REG-SSA-ACROMEGALY - Somatostatin analogue for acromegaly (lanreotide first-generation SSA; pasireotide for SS...